High‐dose therapy and autologous blood stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients

STEM CELLS

Volumn 13, Issue 2 S, 1995, Pages 156-159

  Fermand, J P ^a,b   Ravaud, P ^a,b   Chevret, S ^a,b   Leblond, V ^a,d   Divine, M ^a,e   Dreyfus, F ^a,c   Belanger, ^a,f   Troussard, X ^a,g   Mariette, X ^a,b   Brouet, J C ^a,b  

^a Creteil Hospital   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Hôpital Pitié Salpétrière ^*  (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Autologous blood stem cell transplantation; High dose therapy; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW RESCUE; CANCER COMBINATION CHEMOTHERAPY; CELL TRANSPLANTATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 0029129944     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.5530130725     Document Type: Article

References (6)

1. High‐dose melphalan for multiple myeloma: long‐term follow‐up data
2. Treatment of aggressive multiple myeloma by high‐dose chemotherapy and total body irradiation followed by blood stem cells autologous graft
3. The role of autologous blood stem cells in support of high‐dose therapy for multiple myeloma
4. High‐dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients
5. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high‐dose therapy
6. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high‐dose chemotherapy